HbA1c‑Based Diagnosis of Diabetes in Canada

Diagnostic Threshold and Laboratory Requirements

• Diabetes Canada recommends that a glycated‑hemoglobin (HbA1c) value ≥ 6.5 % (48 mmol/mol) be used as the diagnostic threshold for diabetes in adults, provided the assay is performed in an NGSP‑certified laboratory and is traceable to the DCCT reference method【1】【2】【3】【4】.
• The HbA1c assay must be conducted in a certified laboratory (not point‑of‑care) using an NGSP‑standardized method to ensure accuracy and comparability across sites【3】【4】.

Confirmation Protocol

• When an initial HbA1c result is ≥ 6.5 %, Diabetes Canada requires repeat testing to confirm the diagnosis, unless the patient is in a hyperglycemic crisis or presents classic symptoms with a random plasma glucose ≥ 11.1 mmol/L【3】【4】.
• The preferred confirmatory strategy is to repeat the same HbA1c assay; if the second result is also ≥ 6.5 %, diabetes is confirmed【3】【4】.
• An alternative confirmatory approach allows the use of a different glucose‑based test (fasting plasma glucose or 2‑hour oral glucose tolerance test). Diabetes is confirmed without further testing when both HbA1c ≥ 6.5 % and fasting plasma glucose ≥ 7.0 mmol/L are present【3】【4】.

Situations Where HbA1c Is Not Appropriate

• In individuals with conditions that interfere with HbA1c measurement—such as hemoglobinopathies (e.g., sickle cell disease, HbS, HbC) or altered red‑blood‑cell turnover (e.g., second/third‑trimester pregnancy, hemodialysis, recent transfusion or blood loss, hemolytic anemia, erythropoietin therapy, iron‑deficiency anemia)—Diabetes Canada advises using glucose‑based criteria instead【3】【4】.
• The glucose‑based diagnostic thresholds are fasting plasma glucose ≥ 7.0 mmol/L or 2‑hour OGTT ≥ 11.1 mmol/L when HbA1c cannot be relied upon【1】【2】【3】【4】.

Screening Recommendations for Stroke Patients

• The Canadian Stroke Best Practice Guidelines endorse any of the following as acceptable screening tests for diabetes in patients with stroke: fasting plasma glucose, 2‑hour plasma glucose, HbA1c, or a 75‑g oral glucose tolerance test【1】【2】【5】.
• This endorsement confirms that HbA1c is an accepted screening and diagnostic tool across Canadian clinical contexts【1】【2】.

Common Pitfalls and Quality Assurance

• Diabetes should never be diagnosed on a single HbA1c value without repeat confirmation, except in the setting of a hyperglycemic crisis【3】【4】.
• Point‑of‑care HbA1c devices are not suitable for diagnostic purposes; only certified laboratory methods should be used【3】【4】.
• HbA1c criteria must not be applied when conditions affecting red‑blood‑cell turnover are present, to avoid misclassification【3】【4】.
• Laboratories should ensure proper sample handling; marked discordance between HbA1c and plasma glucose values should trigger investigation for assay interference【3】【4】.

Confirming Diabetes Diagnosis

Timing of Confirmatory Testing

• The American Diabetes Association recommends that for patients with an initial abnormal test result suggesting diabetes, the second confirmatory test should be performed without delay unless there is a clear clinical diagnosis of diabetes 6, 7
• For patients with test results near the margins of the diagnostic threshold, healthcare professionals should follow the patient closely and repeat the test in 3-6 months 6, 7, 8
• In cases of unequivocal hyperglycemia, confirmation with a second test is not necessary 6, 9

Confirmation Methods

• It is preferable to repeat the same test for confirmation, as there will be a greater likelihood of concurrence 10, 11
• If two different tests are available and both are above the diagnostic threshold, this confirms the diagnosis without need for further testing 6, 7, 9
• If a patient has discordant results from two different tests, the test result that is above the diagnostic cut point should be repeated 7, 10

Diagnostic Criteria Requiring Confirmation

• Fasting plasma glucose (FPG) ≥126 mg/dL after at least 8 hours of fasting is a diagnostic criterion for diabetes 6, 12
• 2-hour plasma glucose ≥200 mg/dL during an oral glucose tolerance test (OGTT) is a diagnostic criterion for diabetes 6, 12
• A1C ≥6.5% performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay is a diagnostic criterion for diabetes 6, 12

Special Considerations

• Preanalytic and analytic variability exists for all tests, with A1C having the least variability, followed by FPG, and 2-h PG having the most variability 7, 10
• For plasma glucose samples, it is critical that samples be spun and separated immediately after they are drawn to prevent preanalytic variability 6, 7
• In conditions with abnormal red blood cell turnover, only plasma glucose criteria should be used for diagnosis 6, 12

Clinical Examples

• If the A1C is 7.0% and a repeat result is 6.8%, the diagnosis of diabetes is confirmed 6, 7
• If a patient meets the diabetes criterion of A1C but not FPG, that person should nevertheless be considered to have diabetes 6, 7

Common Pitfalls to Avoid

• Failing to consider factors that may affect A1C reliability can lead to inaccurate diagnosis 6, 12
• Not properly handling plasma glucose samples can lead to falsely lower results 6, 7

Diabetes Diagnosis After Massive Blood Transfusion

Reliability of HbA1c Post‑Transfusion

• The American Diabetes Association (ADA) recommends that in any condition with increased red‑blood‑cell turnover—such as recent major blood loss or transfusion—diagnosis of diabetes should rely on plasma‑glucose criteria rather than HbA1c because donor red cells carry a glycation history that does not reflect the recipient’s recent glycemic control. 13
• After a massive transfusion (e.g., 12 units of packed red blood cells), the circulating hemoglobin is predominantly from donor blood, rendering HbA1c values meaningless for assessing the patient’s true glucose exposure. 14

Timing for HbA1c Measurement

• HbA1c should be deferred for at least 3–4 months after the transfusion to allow complete turnover of the transfused red cells (average red‑cell lifespan ≈120 days). 14
• Once this interval has elapsed, the patient’s own newly produced red cells will dominate the circulation, providing an accurate reflection of chronic glycemic exposure. 14

Alternative Plasma‑Glucose Testing (During the Waiting Period)

• Fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L) after ≥ 8 hours of fasting can be used for diabetes diagnosis. 13
• 2‑hour oral glucose tolerance test (75 g glucose) with plasma glucose ≥ 200 mg/dL (11.1 mmol/L) is diagnostic. 14
• Random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) in the presence of classic hyperglycemia symptoms also meets diagnostic criteria. 13

Technical Requirements for Plasma‑Glucose Testing

• Blood samples must be centrifuged and plasma separated immediately after collection to prevent glycolysis‑induced falsely low glucose values. 14
• Patients should consume at least 150 g of carbohydrate daily for three days before an oral glucose tolerance test to avoid artificially elevated results caused by prior carbohydrate restriction. 14

Clinical Considerations in Acute Critical Illness

• Stress‑induced hyperglycemia is common in severe acute illness (e.g., after major surgery) and does not necessarily indicate underlying diabetes. The ADA notes this distinction when interpreting glucose results. 13
• For inpatient glucose monitoring, point‑of‑care capillary glucose testing is preferred over attempting to interpret HbA1c values during the acute phase. 14

Common Pitfalls to Avoid

• Do not use HbA1c for diabetes diagnosis or monitoring within 3–4 months of a massive transfusion; the result will be unreliable. 13
• A “normal” HbA1c obtained immediately after transfusion may be falsely low because donor red cells dilute the patient’s own glycated hemoglobin, so diabetes cannot be ruled out on this basis alone. 14
• When marked discrepancies appear between HbA1c and plasma‑glucose measurements, consider assay interference or conditions affecting red‑cell turnover as possible explanations. 14

A1C Diagnostic Criteria for Diabetes

Diagnostic Threshold

• The American Diabetes Association (ADA) endorses an A1C cutoff of ≥6.5 % (≥48 mmol/mol) for diagnosing diabetes in non‑pregnant adults; this threshold was selected by the International Expert Committee. 15

• An A1C value of ≥6.5 % corresponds to the inflection point where retinopathy prevalence rises, mirroring the epidemiologic relationships of fasting plasma glucose ≥126 mg/dL and 2‑hour plasma glucose ≥200 mg/dL. 15

• The cutoff reflects chronic glycemic exposure over 2–3 months and correlates with both microvascular and macrovascular complications. 15

Laboratory Requirements

• A1C testing must be performed in a laboratory using a method certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized or traceable to the Diabetes Control and Complications Trial (DCCT) reference assay. 15

• Point‑of‑care A1C devices are not sufficiently accurate for diagnostic use and should never be employed to diagnose diabetes. 15

Confirmation Protocol

• When hyperglycemia is not unequivocal (i.e., no hyperglycemic crisis with classic symptoms), an abnormal A1C result must be confirmed by repeat testing. 15

• The preferred confirmation method is to repeat the same A1C assay; if both results are ≥6.5 %, diabetes is confirmed. 16

• Diabetes can also be confirmed without a repeat A1C when two different diagnostic tests (e.g., A1C ≥6.5 % and fasting plasma glucose ≥126 mg/dL) are each above their respective thresholds. 16

• If results from two different tests are discordant, the test that exceeded its diagnostic threshold should be repeated to establish the diagnosis. 16

Situations in Which A1C Should Not Be Used

• Hemoglobinopathies (e.g., sickle cell disease/trait, HbS, HbC) that interfere with the assay render A1C unreliable; use a method without hemoglobin interference or rely exclusively on glucose criteria. 15

• Conditions that alter red‑cell turnover—recent blood loss or transfusion, hemolytic anemia, iron‑deficiency anemia—also invalidate A1C; glucose‑based criteria should be used exclusively. 15

• In the above situations, diagnose diabetes using fasting plasma glucose ≥126 mg/dL (≥7.0 mmol/L) or 2‑hour OGTT ≥200 mg/dL (≥11.1 mmol/L). 15

Alternative Glucose‑Based Diagnostic Criteria

• Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L) after at least 8 hours of fasting. 15

• 2‑hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during a 75‑g oral glucose tolerance test. 15

• Random plasma glucose ≥200 mg/dL (11.1 mmol/L) in a patient with classic hyperglycemia symptoms (polyuria, polydipsia, unexplained weight loss) or in hyperglycemic crisis. 15

Advantages of A1C

• No fasting is required, offering greater convenience for patients and clinicians. 15

• Provides greater pre‑analytical stability and less day‑to‑day variability during stress or illness compared with glucose measurements. 15

• Widely recognized by clinicians as a marker of long‑term glycemic control. 15

Limitations of A1C

• Lower sensitivity than fasting glucose; A1C ≥6.5 % identifies roughly one‑third fewer cases of undiagnosed diabetes than fasting plasma glucose ≥126 mg/dL in population screening. 15

• Higher cost and limited availability in some regions. 15

• Incomplete correlation with average glucose in certain individuals, leading to potential misclassification. 15

• Results can vary by ethnicity and are unreliable in conditions affecting red‑cell turnover. 16

• May not be markedly elevated in rapidly progressing type 1 diabetes in children despite overt hyperglycemia. 15

Clinical Pitfalls and Recommendations

• Do not use point‑of‑care A1C devices for diagnosis; only NGSP‑certified laboratory methods are acceptable. 15

• Always assess for conditions that invalidate A1C (hemoglobinopathies, anemia, recent transfusion, pregnancy); when present, switch to glucose‑based diagnostic criteria. 15

• For patients with borderline A1C values (≈6.4–6.6 %), arrange close follow‑up and repeat testing in 3–6 months to clarify diagnostic status. 17

Diagnostic Confirmation of Diabetes Using Fasting Plasma Glucose

Diagnostic Criteria and Confirmation Requirements

• The American Diabetes Association (ADA) requires two abnormal test results (e.g., fasting plasma glucose ≥ 126 mg/dL or A1c ≥ 6.5%) to confirm a diabetes diagnosis when there is no unequivocal hyperglycemia such as classic symptoms with random glucose ≥ 200 mg/dL. 18

Recommended Repeat Testing Protocol

• Repeat the fasting plasma glucose (FPG) within days to weeks after the initial abnormal result, using an 8‑hour fast, a certified laboratory, and the same assay method; point‑of‑care glucometers are not acceptable for diagnostic confirmation. 18

Interpretation of Repeat Fasting Plasma Glucose

Interpretation applies to the repeat FPG performed as described above. 18

Role of the Oral Glucose Tolerance Test (OGTT)

• An OGTT adds no diagnostic value when a fasting plasma glucose already meets the diabetes threshold; it is one of four equivalent diagnostic criteria (fasting glucose, A1c, random glucose with symptoms, OGTT) but not a confirmatory test for discordant results. 18
• The OGTT is more cumbersome, time‑consuming, and poorly reproducible than repeating an FPG, and is mainly useful for detecting isolated post‑prandial hyperglycemia when both fasting glucose and A1c are normal. 18

Managing A1c–Glucose Discordance

• A pattern of A1c = 6.4 % (prediabetes range) with FPG = 134 mg/dL (diabetes range) is a common discordance that does not require an OGTT for resolution. 18
• Possible explanations include:
  • Predominantly fasting hyperglycemia with less post‑prandial elevation.
  • Conditions that falsely lower A1c, such as hemoglobinopathies, increased red‑cell turnover (e.g., recent blood loss, hemolysis), G6PD deficiency, or erythropoietin therapy. 18
• If marked discordance persists after repeat testing, investigate assay interference or underlying conditions affecting red‑cell turnover. 18

Common Pitfalls to Avoid

• Do not diagnose diabetes on a single FPG = 134 mg/dL without repeat confirmation; this violates ADA standards and risks misdiagnosis. 18
• Do not order an OGTT when a fasting glucose already exceeds the diabetes threshold; repeat the fasting glucose instead. 18
• Do not wait 3–6 months to repeat testing; the appropriate interval after an abnormal result is days to weeks. 18
• Do not use point‑of‑care glucose meters for diagnostic confirmation; only certified laboratory plasma glucose measurements are acceptable. 18

Factors That May Elevate an Initial Fasting Glucose

• Inadequate fasting (less than 8 hours or any caloric intake). 18
• Recent acute illness or physiological stress. 18
• Medications that raise glucose, such as corticosteroids or thiazide diuretics. 18

Summary Recommendations

• Repeat the fasting plasma glucose within days to weeks in a certified laboratory after an 8‑hour fast.
• If the repeat FPG is ≥ 126 mg/dL, diabetes is confirmed and management should be initiated.
• If the repeat FPG is 100–125 mg/dL, the patient has prediabetes and should receive intensive lifestyle intervention with annual monitoring.
• An OGTT is not warranted in this scenario. 18